Emergent BioSolutions Inc. (EBS) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Emergent BioSolutions Inc...

    NYSE: EBS · Real-Time Price · USD
    9.14
    -0.05 (-0.54%)
    At close: Oct 03, 2025, 3:59 PM
    9.05
    -0.98%
    After-hours: Oct 03, 2025, 07:54 PM EDT

    Emergent BioSolutions Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 1.01B 1.05B 1.12B 1.79B
    Cost of Revenue
    		 1.00 705.4M 693.7M 757.5M
    Gross Profit
    		 305.2M 343.9M 427.2M 1.04B
    Operating Income
    		 -108.7M -726.4M -166M 352.6M
    Interest Income
    		 n/a n/a n/a n/a
    Pretax Income
    		 -142.9M -731.2M -221.7M 314.4M
    Net Income
    		 -190.6M -760.5M -223.8M 219.5M
    Selling & General & Admin
    		 308M 368.4M 340.3M 348.4M
    Research & Development
    		 70.7M 111.4M 193M 234M
    Other Expenses
    		 773.6M 564.2M 59.9M 58.5M
    Operating Expenses
    		 1.15B 1.04B 593.2M 640.9M
    Interest Expense
    		 71M 87.9M 37.3M 34.5M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 1.12B 1.78B 1.29B 1.4B
    Income Tax Expense
    		 47.7M 29.3M 2.1M 83.5M
    Shares Outstanding (Basic)
    		 53M 51.2M 50.1M 53.5M
    Shares Outstanding (Diluted)
    		 53M 51.2M 50.1M 54.1M
    EPS (Basic)
    		 -3.6 -14.85 -4.47 4.10
    EPS (Diluted)
    		 -3.6 -14.85 -4.47 4.06
    EBITDA
    		 36.9M -505.3M -32.9M 458.2M
    EBIT
    		 -71.9M -643.3M -181.7M 331.9M
    Depreciation & Amortization
    		 108.8M 125.1M 148.9M 126.3M

    Add to Watchlist